
Ventas (VTR) Stock Forecast & Price Target
Ventas (VTR) Analyst Ratings
Bulls say
Ventas is supported by a diversified healthcare real estate platform of nearly 1,400 properties across senior housing, medical office, hospital, life science, and skilled nursing/post-acute care, plus a small loan portfolio that contributes about 1% of NOI. Its positive outlook is anchored in strong SHOP operating momentum, with same-store NOI growth of 15.4% in 1Q26 and 15.9% YTD, alongside elevated occupancy and management guidance of 15-17% full-year growth in 2026. The company also has a robust investment runway, targeting about $3.0 billion of annual acquisitions in 2026 with deals still underwriting to low- to mid-teens IRRs, while net debt to EBITDA improved to 5.0x in 1Q26 and the stock benefits from a leading sustainability profile.
Bears say
Ventas is exposed to a potentially less favorable mix of healthcare real estate risks, as its nearly 1,400-property portfolio spans senior housing, medical office, hospitals, life science, and skilled nursing/post-acute care, with about 100 assets in Canada and the United Kingdom and mortgages/loans adding only about 1% of NOI. The bearish view is driven by the expectation that today’s elevated seniors housing growth normalizes back toward historical ranges, which would compress valuation multiples and temper the company’s 7-year growth outlook despite still-respectable fundamentals. Additional pressure could come from tighter capital availability, rising competition from private buyers, renewed supply in SHOP, and regulatory or NIH budget changes that could affect its 8% Wexford/R&I exposure.
This aggregate rating is based on analysts' research of Ventas and is not a guaranteed prediction by Public.com or investment advice.
Ventas (VTR) Analyst Forecast & Price Prediction
Start investing in Ventas (VTR)
Order type
Buy in
Order amount
Est. shares
0 shares